BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis |
|
|
| Recruiting | 3 | 156 | US | Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™) | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc. | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 10/26 | 10/29 | | |
| Completed | N/A | 21 | US | Cubii elliptical | University of Washington | Multiple Sclerosis, Fatigue, Activity, Motor, Quality of Life | 08/23 | 12/23 | | |
NCT05252195: Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS) |
|
|
| Active, not recruiting | N/A | 300 | US | | University of Michigan, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Wayne State University, University of Washington | Multiple Sclerosis | 03/27 | 03/27 | | |
